Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autoimmune hepatitis and overlap syndromes.

Arndt Vogel1, Heiner Wedemeyer, Michael P Manns

  • 1Department of Hepatology, Gastroenterology and Endocrinology, Hannover Medical School, Hannover, Germany.

Journal of Gastroenterology and Hepatology
|December 11, 2002
PubMed
Summary

Autoimmune hepatitis, a chronic liver disease, is typically treated with steroids and azathioprine, achieving remission in 90% of patients. However, long-term remission after drug withdrawal is rare, necessitating ongoing research into alternative therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial.

JAMA oncology·2026
Same author

Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.

Journal of hepatology·2026
Same author

A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients.

International journal of cancer·2026
Same author

Trends in the incidence and surgical treatment of hepatocellular carcinoma in Ontario.

Canadian journal of surgery. Journal canadien de chirurgie·2026
Same author

Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.

Nature reviews. Clinical oncology·2026

Area of Science:

  • Hepatology
  • Immunology
  • Internal Medicine

Background:

  • Autoimmune hepatitis is a chronic liver disease predominantly affecting women.
  • Characterized by autoantibodies, elevated gammaglobulins, and associated extrahepatic immune-mediated syndromes.
  • Current treatment relies on steroid monotherapy or combination therapy with azathioprine, with high initial efficacy.

Purpose of the Study:

  • To review current treatment strategies for autoimmune hepatitis.
  • To discuss challenges in remission induction and maintenance therapy.
  • To highlight the significance of overlap syndromes in difficult-to-treat cases.

Main Methods:

  • Review of established treatment regimens for autoimmune hepatitis.
  • Discussion of therapeutic options for treatment failure and steroid-sparing strategies.

Related Experiment Videos

  • Analysis of diagnostic parameters including serological, biochemical, clinical, and histological findings.

    • Main Results:

    • Medical therapy achieves remission in approximately 90% of autoimmune hepatitis patients.
    • Long-term remission after drug withdrawal is achieved in only 17% of patients, necessitating lifelong treatment.
    • Treatment failure occurs in about 10% of cases, requiring advanced immunosuppressants.

    Conclusions:

    • Standard therapies are effective for remission induction but often require lifelong administration.
    • Minimizing steroid side effects and managing treatment failure are key challenges.
    • Overlap syndromes, such as with primary biliary cirrhosis or primary sclerosing cholangitis, are crucial considerations in complex cases.